Evidence map›Paper›PMID 40851910›Full record

ReviewGynecologic oncology reports2025

Ivermectin and gynecologic cancer: What's the data?

Vaidehi Mujumdar, Marilyn Huang, Lindsey Chippendale Smith, Fernanda Musa

Abstract readReview
In one paragraph

Review in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Vaidehi MujumdarAtrium Health Levine Cancer Institute, 1021 Morehead Drive, Suite 2100, Charlotte, NC 28202, USA.
Marilyn HuangUniversity of Virginia School of Medicine, P.O. Box 800712, Charlottesville, VA 22908, USA.
Lindsey Chippendale SmithUniversity of Virginia Health, 1215 Lee Street, Charlottesville, VA 22903, USA.
Fernanda MusaProvidence-Swedish Cancer Institute, 1101 Madison St Suite 1500, Seattle, WA 98104, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

•Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.•The data on ivermectin as a gynecologic cancer-fighting compound is lacking.•Clinical studies on ivermectin use in cancer are limited to effects observed in cell lines.•We have not assessed ivermectin's safety and efficacy in gynecologic cancers.•We do not recommend and strongly caution the use of ivermectin in the treatment of gynecologic cancers.

Indexed as

Anti-helminthicCOVID-19Gynecologic cancersIvermectinWonder drug

Identifiers

PMID40851910
PMCPMC12369425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.